表紙
市場調査レポート

米国の病院での微生物検査市場

US Hospital Infectious Disease Market: Emerging Opportunities and Growth Strategies for Suppliers

発行 Venture Planning Group 商品コード 259619
出版日 ページ情報 英文 997 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。

Local License: 同一事業所内

Back to Top
米国の病院での微生物検査市場 US Hospital Infectious Disease Market: Emerging Opportunities and Growth Strategies for Suppliers
出版日: ページ情報: 英文 997 Pages
担当者のコメント
このシリーズは、他にも調査対象国がございます。詳細はお問合せください。
概要

当レポートでは、米国の病院検査室での微生物検査関連市場について分析し、市場への様々な影響要因(経済・規制・人口・社会・技術的側面)や、研究開発の最新動向と将来展望、今後10年間の市場動向(試薬・検査機器などの販売量・販売額などの予測値)、主な分析装置の機能比較、新たな診断技術とその潜在的用途、主な製品開発機会、主要企業プロファイルなどを調査して、その結果を概略以下の構成でお届けします。

イントロダクション

世界市場と技術概要

  • 主な感染症の検査(全68種)
    • エイズ(AIDS)
    • アデノウイルス
    • エロモナス
    • 炭疽病/炭疽菌
    • アルボウイルス
    • バベシア症
    • 細菌性血管腫症(BEA)
    • ブルセラ菌
    • カンピロバクター
    • カンジダ
    • シャーガス病
    • 軟性下疳
    • クラミジア
    • クロストリジウム・ディフィシレ
    • コロナウイルス
    • コクサッキーウイルス
    • クロイツフェルト・ヤコブ病
    • クリプトスポリジウム
    • シクロスポラ
    • サイトメガロ・ウイルス
    • エボラウイルス
    • 大腸菌
    • エコー・ウイルス
    • 脳炎
    • エンテロウイルス
    • エプスタイン・バーウイルス
    • ランブル鞭毛虫
    • 淋病
    • 鼠径部肉芽腫
    • ハンタウイルス
    • ピロリ菌
    • 肝炎
    • 単純ヘルペスウイルス
    • ヒトヘルペス・ウイルス6型
    • インフルエンザウイルス
    • レジオネラ
    • ライム病
    • 鼠径リンパ肉芽腫
    • マラリア
    • はしか
    • 髄膜炎
    • 微胞子虫目
    • 単核症
    • おたふく風邪
    • マイコプラズマ
    • パピロマウイルス
    • パルボウイルス B19
    • 肺炎
    • ポリオーマウイルス
    • 緑膿菌
    • 狂犬病
    • 呼吸器合胞体ウイルス
    • ライノウイルス
    • ロタウイルス
    • 風疹
    • サルモネラ菌
    • 敗血症
    • 細菌性赤痢
    • 黄色ブドウ球菌
    • 連鎖球菌
    • 梅毒
    • トキソプラズマ症
    • 膣トリコモナス
    • 結核
    • ビブリオ
    • 西ナイルウイルス
    • エルシニア
  • 代表的な解析装置のレビュー(発売元:Abbott、Beckman Coulter/Danaher、BioMerieux、Ortho-Clinical Diagnostics、Roche、Siemens、東ソー、Wallacほか)
  • 新規の診断技術
    • DNAプローブ
    • モノクローナル抗体
    • 免疫学的検定
    • 差分光散乱
    • マイクロコンピュータ・オートメーション
    • 人工知能
    • リポソーム
    • フローサイトメトリ
    • クロマトグラフィ
    • MRI
    • ゲル微液滴
    • その他

米国市場

  • エグゼクティブ・サマリー
  • ビジネス環境
    • 医療費支出
    • コスト意識
    • 医療費還付
    • 産業内の企業統合
    • マネージドケア(管理型医療)
    • 病院
    • 入院
    • 滞在期間
    • 産業の多様化
    • 医師の人口構成
    • 人口の高齢化
    • 研究機関に対する規制
    • FDAの改革
  • 市場構造
    • 集中型検査
    • 分散型検査
  • 市場規模・成長率・主要サプライヤー

主な製品開発機会

  • 機器
  • 試薬キットおよび検査システム/パネル
  • コンピューター・ソフトウェア・オートメーション
  • 補助製品

分散型検査製品の設計基準

代替的な市場浸透戦略

  • 内部開発
  • 共同事業協定
  • 大学との契約
  • 分散型検査市場の流通戦略
    • マーケティングのアプローチ
    • 製品の複雑性
    • 顧客の選好
    • 既存のサプライヤー
    • 新規参入サプライヤー
    • 主な種類の流通業者
    • 市場の分類

潜在的な市場参入障壁とリスク

  • 市場の成熟化
  • コスト抑制
  • 競争
  • 技術の限界
  • 特許保護
  • 規制による抑制
  • 分散型検査市場の課題

競合企業分析

  • Abbott
  • Affymetrix
  • BBeckman Coulter/Danaher
  • Becton Dickinson
  • bioMerieux
  • Bio-Rad
  • Cepheid
  • Diamedix
  • DiaSorin
  • 栄研化学
  • Enzo Biochem
  • 富士レビオ
  • Gen-Probe
  • Hologic
  • ID Biomedical
  • Innogenetics/Solvay
  • Kreatech
  • Life Technology
  • Lonza
  • Nanogen/Elitech
  • Novartis Diagnostics
  • Qiagen
  • Roche
  • Scienion
  • Sequenom
  • SeraCare
  • Siemens
  • タカラバイオ
  • Thermo Fisher
  • Wallac
  • 和光純薬工業

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: VPID19608

This new report from VPGMarketResearch.com contains 997 pages, 87 tables, and presents a comprehensive analysis of the US hospital infectious disease testing market, including: 

  • Major issues pertaining to the US hospital laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years. 
  • Current scientific views on definition, epidemiology, and etiology of major infectious diseases and microorganisms. 
  • Volume and sales forecasts for 80 infectious disease tests performed in US hospital laboratories. 
  • Instrumentation technologies and feature comparison of leading analyzers. 
  • Sales and market shares of leading suppliers by test. 
  • Emerging diagnostic technologies and their potential market applications. 
  • Product development opportunities. 
  • Profiles of current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies.  
  • Business opportunities and strategic recommendations for suppliers. 

         Contains 997 pages and 87 tables

 

Table of Contents

Introduction

Worldwide Market and Technology Overview

  • A. Major Infectious Disease Tests
    • 1. AIDS
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
    • 2. Adenovirus
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
      • d. Adeno-Associated Viruses(AAV)
    • 3. Aeromonas
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
    • 4. Anthrax/Bacillus Anthracis
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
    • 5. Arboviruses
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
    • 6. Babesiosis
      • a. Background
    • 7. Bacillary Epithelioid Angiomatosis (BEA) And Other Bartonella (Rochalimaea)
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
    • 8. Blastocystis Hominis
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
    • 9. Brucella
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
    • 10. Campylobacter
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
    • 11. Candida
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
    • 12. Chagas Disease
      • a. Background
    • 13. Chancroid
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
    • 14. Chlamydia
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
    • 15. Clostridium Difficile
      • a. Background
      • b. Diagnostic Tests
      • c. Drugs and Vaccines
    • 16. Coronaviruses
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
    • 17. Coxsackieviruses
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
    • 18. Creutzfeldt-Jakob's Disease
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines
    • 19. Cryptosporidium Parvum
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
    • 20. Cyclospora Cayetanensis
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
    • 21. Cytomegalovirus
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
    • 22. Ebola Virus
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
    • 23. E. Coli
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
    • 24. EchoVirus
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
    • 25. Encephalitis
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
    • 26. Enteroviruses
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
    • 27. Epstein-Barr Virus
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
    • 28. Giardia Lamblia
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
    • 29. Gonorrhea
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
    • 30. Granuloma Inguinale
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
    • 31. Hantavirus
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
    • 32. Helicobacter Pylori
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
    • 33. Hepatitis
      • a. Background
      • b. Hepatitis A
      • c. Hepatitis B
      • d. Hepatitis C
      • e. Vaccines and Drugs
    • 34. Herpes Simplex Virus
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
    • 35. Human Herpes Virus-6 (HHV-6)
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
    • 36. Influenza Viruses
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
    • 37. Legionella
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
    • 38. Lyme Disease
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
    • 39. Lymphogranuloma Venereum (LGV)
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
    • 40. Malaria
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
    • 41. Measles (Rubeola)
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
    • 42. Meningitis
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
    • 43. Microsporidium
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
    • 44. Mononucleosis
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
    • 45. Mumps
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
    • 46. Mycoplasma
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
    • 47. Papillomaviruses
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
    • 48. Parvovirus B19
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
    • 49. Pneumonia
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
    • 50. Polyomaviruses
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
    • 51. Pseudomonas Aeruginosa
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
    • 52. Rabies
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
    • 53. Respiratory Syncytial Virus (RSV)
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
    • 54. RhinoViruses
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
    • 55. RotaVirus (REOVIRUS)
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
    • 56. Rubella(MEASLES)
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
    • 57. Salmonellosis
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
    • 58. Septicemia
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
    • 59. Shigellosis
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
    • 60. Staphylococcus Aureus
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
    • 61. Streptococci
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
    • 62. Syphilis
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
    • 63. Toxoplasmosis
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
    • 64. Trichomonas Vaginalis
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
    • 65. Tuberculosis
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
    • 66. Vibrio
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
    • 67. West Nile Virus
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
    • 68. Yersina
      • a. Background
      • b. Diagnostic Tests
      • c. Vaccines and Drugs
  • B. Instrumentation Review of Leading Analyzers Marketed by Abbott, Beckman Coulter/Danaher, BioMerieux, Ortho-Clinical Diagnostics, Roche, Siemens, Tosoh, Wallac and Other Suppliers
  • C. Emerging Diagnostic Technologies
    • 1. Molecular Diagnostics
    • 2. Monoclonal Antibodies
    • 3. Immunoassays
    • 4. Differential Light Scattering
    • 5. Information Technology
    • 6. Artificial Intelligence
    • 7. Liposomes
    • 8. Flow Cytometry
    • 9. Chromatography
    • 10. Diagnostic Imaging
    • 11. Gel Microdroplets
    • 12. Other

U.S.A.

  • A. Executive Summary
  • B. Business Environment
    • 1. Health Care Expenditures
    • 2. Cost Consciousness
    • 3. Reimbursement
    • 4. Industry Consolidation
    • 5. Managed Care
      • a. HMO
      • b. PPO
    • 6. Hospitals
    • 7. Admissions
    • 8. Length of Stay
    • 9. Industry Diversification
    • 10. Physician Demographics
    • 11. Population Aging
      • a. Chronic Illness
      • b. Disease Incidence
      • c. Susceptibility to Iatrogenesis
      • d. Multiple Illness Cases
    • 12. Laboratory Regulations
    • 13. FDA Reform
  • C. Market Structure
    • 1. Centralized Testing
      • a. Hospitals
      • b. Commercial/Private Laboratories
      • c. Blood Banks
        • 1) Community and Regional Centers
        • 2) Plasma Fractionation Centers
    • 2. Decentralized Testing
      • a. Physician Offices/Group Practices
      • b. Point of Care Testing
      • c. Other Decentralized Testing Locations
  • D. Market Size, Growth and Major Suppliers

Major Product Development Opportunities

  • A. Instrumentation
  • B. Reagent Kits and Test Systems/Panels
  • C. Computers, Software and Automation
  • D. Auxiliary Products

Design Criteria for Decentralized Testing Products

Alternative Market Penetration Strategies

  • A. Internal Development
  • B. Collaborative Arrangements
  • C. University Contracts
  • D. Distribution Strategies for Decentralized Testing Markets
    • 1. Marketing Approaches
    • 2. Product Complexity
    • 3. Customer Preference
    • 4. Established Suppliers
    • 5. Emerging Suppliers
    • 6. Major Types of Distributors
    • 7. Market Segmentation

Potential Market Entry Barriers and Risks

  • A. Market Maturity
  • B. Cost Containment
  • C. Competition
  • D. Technological Edge and Limitations
  • E. Patent Protection
  • F. Regulatory Constraints
  • G. Decentralized Testing Market Challenges

Competitive Assessments

  • Abbott
  • Affymetrix
  • Beckman Coulter/Danaher
  • Becton Dickinson
  • bioMerieux
  • Bio-Rad
  • Cepheid
  • Diamedix
  • DiaSorin
  • Eiken Chemical
  • Enzo Biochem
  • Fujirebio
  • Gen-Probe
  • Hologic
  • ID Biomedical
  • Innogenetics/Solvay
  • Kreatech
  • Life Technology
  • Lonza
  • Nanogen/Elitech
  • Novartis Diagnostics
  • Ortho-Clinical Diagnostics
  • Qiagen
  • Roche
  • Scienion
  • Sequenom
  • SeraCare
  • Siemens
  • Takara Bio
  • Thermo Fisher
  • Wallac
  • Wako

List of Tables

  • Major Companies Developing or Marketing AIDS Tests
  • Major Companies Developing or Marketing Adenovirus Tests
  • Major Companies Developing or Marketing Bartonella Tests
  • Major Companies Developing or Marketing Campylobacter Tests
  • Major Companies Developing or Marketing Candida Tests
  • Major Companies Developing or Marketing Chlamydia Tests
  • Major Companies Developing or Marketing Clostridium Tests
  • Major Companies Developing or Marketing Coronavirus Tests
  • Major Companies Developing or Marketing Cryptosporidium Tests
  • Major Companies Developing or Marketing CMV Tests
  • Major Companies Developing or Marketing Echovirus Tests
  • Major Companies Developing or Marketing Enterovirus Tests
  • Major Companies Developing or Marketing EBV Tests
  • Major Companies Developing or Marketing Giardia Tests
  • Major Companies Developing or Marketing Gonorrhea Tests
  • Major Companies Developing or Marketing Hantavirus Tests
  • Major Companies Developing or Marketing Helicobacter Pylori Tests
  • Major Companies Developing or Marketing Hepatitis Tests
  • Major Companies Developing or Marketing Herpes Tests
  • Major Companies Developing or Marketing Influenza Tests
  • Major Companies Developing or Marketing Legionella Tests
  • Major Companies Developing or Marketing Lyme Disease Tests
  • Major Companies Developing or Marketing Lymphogranuloma Tests
  • Major Companies Developing or Marketing Malaria Tests
  • Major Companies Developing or Marketing Measles Tests
  • Major Companies Developing or Marketing Meningitis Tests
  • Major Companies Developing or Marketing Microsporidium Tests
  • Major Companies Developing or Marketing Mononucleosis Tests
  • Major Companies Developing or Marketing Mumps Tests
  • Major Companies Developing or Marketing Mycoplasma Tests
  • Major Companies Developing or Marketing Papilloma Virus Tests
  • Major Companies Developing or Marketing Parvovirus Tests
  • Major Companies Developing or Marketing Pneumonia Tests
  • Major Companies Developing or Marketing RSV Tests
  • Major Companies Developing or Marketing Rotavirus Tests
  • Major Companies Developing or Marketing Rubella Tests
  • Major Companies Developing or Marketing Salmonella Tests
  • Major Companies Developing or Marketing Septicemia Tests
  • Major Companies Developing or Marketing Shigella Tests
  • Major Companies Developing or Marketing Staphylococci Tests
  • Major Companies Developing or Marketing Streptococci Tests
  • Major Companies Developing or Marketing Syphilis Tests
  • Major Companies Developing or Marketing Toxoplasmosis Tests
  • Major Companies Developing or Marketing Trichomonas Tests
  • Major Companies Developing or Marketing Tuberculosis Tests
  • Major Companies Developing or Marketing West Nile Tests
  • Major Companies Developing or Marketing Yersinia Tests
  • U.S.A. Summary Table
  • All Infectious Diseases Test Volume and Diagnostics Sales Forecast
  • U.S.A.
  • Hospital Laboratories Performing Infectious Disease Tests by Bed Size
  • U.S.A.
  • Hospital Laboratories Infectious Disease Test Volume Forecast
  • U.S.A.
  • Hospital Laboratories Infectious Disease Diagnostics Market Forecast
  • U.S.A.
  • AIDS Testing Market Diagnostics Sales by Major Supplier
  • U.S.A.
  • Adenovirus Testing Market Diagnostics Sales by Major Supplier
  • U.S.A.
  • Campylobacter Testing Market Diagnostics Sales by Major Supplier
  • U.S.A.
  • Candida Testing Market Diagnostics Sales by Major Supplier
  • U.S.A.
  • Chancroid Testing Market Diagnostics Sales by Major Supplier
  • U.S.A.
  • Chlamydia Testing Market Diagnostics Sales by Major Supplier
  • U.S.A.
  • CMV Testing Market Diagnostics Sales by Major Supplier
  • U.S.A.
  • Cryptosporidium Testing Market Diagnostics Sales by Major Supplier
  • U.S.A.
  • Echovirus Testing Market Diagnostics Sales by Major Supplier
  • U.S.A.
  • Enterovirus Testing Market Diagnostics Sales by Major Supplier
  • U.S.A.
  • EBV Testing Market Diagnostics Sales by Major Supplier
  • U.S.A.
  • Giardia Testing Market Diagnostics Sales by Major Supplier
  • U.S.A.
  • Gonorrhea Testing Market Diagnostics Sales by Major Supplier
  • U.S.A.
  • Helicobacter Pylori Testing Market Diagnostics Sales by Major Supplier
  • U.S.A.
  • Hepatitis Testing Market Diagnostics Sales by Major Supplier
  • U.S.A.
  • Hepatitis C Testing Market Diagnostics Sales by Major Supplier
  • U.S.A.
  • Herpes Testing Market Diagnostics Sales by Major Supplier
  • U.S.A.
  • Influenza Testing Market Diagnostics Sales by Major Supplier
  • U.S.A.
  • Legionella Testing Market Diagnostics Sales by Major Supplier
  • U.S.A.
  • Lyme Disease Testing Market Diagnostics Sales by Major Supplier
  • U.S.A.
  • Measles Testing Market Diagnostics Sales by Major Supplier
  • U.S.A.
  • Meningitis Testing Market Diagnostics Sales by Major Supplier
  • U.S.A.
  • Mononucleosis Testing Market Diagnostics Sales by Major Supplier
  • U.S.A.
  • Mumps Testing Market Diagnostics Sales by Major Supplier
  • U.S.A.
  • Mycoplasma Testing Market Diagnostics Sales by Major Supplier
  • U.S.A.
  • Pneumonia Testing Market Diagnostics Sales by Major Supplier
  • U.S.A.
  • Rabies Testing Market Diagnostics Sales by Major Supplier
  • U.S.A.
  • RSV Testing Market Diagnostics Sales by Major Supplier
  • U.S.A.
  • Rotavirus Testing Market Diagnostics Sales by Major Supplier
  • U.S.A.
  • Rubella Testing Market Diagnostics Sales by Major Supplier
  • U.S.A.
  • Salmonella Testing Market Diagnostics Sales by Major Supplier
  • U.S.A.
  • Septicemia Testing Market Diagnostics Sales by Major Supplier
  • U.S.A.
  • Shigella Testing Market Diagnostics Sales by Major Supplier
  • U.S.A.
  • Streptococci Testing Market Diagnostics Sales by Major Supplier
  • U.S.A.
  • Syphilis Testing Market Diagnostics Sales by Major Supplier
  • U.S.A.
  • Toxoplasmosis Testing Market Diagnostics Sales by Major Supplier
Back to Top